Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis

Published byAri Sutedja Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis"— Presentation transcript:

1 Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis
Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis. Dashed line indicates a suggested, non-mandatory ... Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis. Dashed line indicates a suggested, non-mandatory step. AL, amyloid light-chain amyloidosis; ATTR, amyloid transthyretin amyloidosis (ATTRv, variant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis); CMR, cardiac magnetic resonance; HF, heart failure. Modified from Gillmore et al.<sup>11</sup> Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz298, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Take home figure The pathogenetic cascade of cardiac transthyretin (TTR) amyloidosis and proposed therapeutic approaches for ... Take home figure The pathogenetic cascade of cardiac transthyretin (TTR) amyloidosis and proposed therapeutic approaches for each step. The more promising approaches, for which a phase 3 study is available, are evidenced in bold, while the least established options are reported in brackets. Ab, antibody; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blockers; ASO, antisense oligonucleotide; BB, beta-blockers; EGCG, epigallocatechin gallate; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular assist device; ATTRv, variant transthyretin amyloidosis; MRA, mineralocorticoid receptor antagonists; PM, pacemaker; SAP, serum amyloid P component; siRNA, small interfering RNA; TUDCA, tauroursodeoxycholic acid. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz298, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Diagnostic algorithm for cardiac transthyretin amyloidosis"

Similar presentations

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 3 Doctors leaving (Matthews, 2013, p.13.)

Figure 3 Doctors leaving (Matthews, 2013, p.13.)
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Medicaid receipt and ACA favorability

Figure 1. Medicaid receipt and ACA favorability
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.

Similar presentations

Ads by Google